Kim Jong Ho, Lim Man-Sup, Choi Jun Woo, Kim Haewon, Kwon Young-Suk, Lee Jae Jun
Department of Anesthesiology and Pain Medicine, Chuncheon Sacred Heart Hospital, College of Medicine, Hallym University, Chuncheon 24253, Korea.
Institute of New Frontier Research Team, Hallym University, Chuncheon 24253, Korea.
J Clin Med. 2020 Oct 28;9(11):3477. doi: 10.3390/jcm9113477.
Thus far, few studies have compared the effects of sugammadex and cholinesterase inhibitors on postoperative nausea and vomiting (PONV), and the results have been controversial. Here, we compared the effects of sugammadex, neostigmine, and pyridostigmine on PONV by means of a five hospital analysis with propensity score matching. We analyzed adults aged ≥ 18 years who underwent general anesthesia between January 2014 and December 2019. Following propensity score matching, 7793 patients were included in each of the neostigmine and sugammadex matched patient groups (absolute standardized difference (ASD), 0.01-0.07), and 10,197 patients were included in each of the pyridostigmine and sugammadex matched patient groups (ASD, 0.01-0.02), while 19,377 patients were included in each of the pyridostigmine and neostigmine matched patient groups. (ASD, 0.01-0.19). The odds of PONV were low in the sugammadex group (odds ratio, 0.65; 95% confidence interval, 0.59-0.72; < 0.0001) and pyridostigmine group (odds ratio, 0.22; 95% confidence interval, 0.20-0.24; < 0.0001) compared to the neostigmine group, while there was no difference between sugammadex and pyridostigmine (odds ratio, 0.95; 95% confidence interval, 0.86-1.04; = 0.281). Therefore, sugammadex and pyridostigmine may lower the incidence of PONV compared to neostigmine in patients undergoing general anesthesia.
迄今为止,很少有研究比较舒更葡糖钠和胆碱酯酶抑制剂对术后恶心呕吐(PONV)的影响,结果存在争议。在此,我们通过一项五家医院的倾向评分匹配分析,比较了舒更葡糖钠、新斯的明和吡啶斯的明对PONV的影响。我们分析了2014年1月至2019年12月期间接受全身麻醉的≥18岁成年人。经过倾向评分匹配后,新斯的明和舒更葡糖钠匹配患者组每组纳入7793例患者(绝对标准化差异(ASD),0.01 - 0.07),吡啶斯的明和舒更葡糖钠匹配患者组每组纳入10197例患者(ASD,0.01 - 0.02),而吡啶斯的明和新斯的明匹配患者组每组纳入19377例患者(ASD,0.01 - 0.19)。与新斯的明组相比,舒更葡糖钠组(比值比,0.65;95%置信区间,0.59 - 0.72;<0.0001)和吡啶斯的明组(比值比,0.22;95%置信区间,0.20 - 0.24;<0.0001)发生PONV的几率较低,而舒更葡糖钠和吡啶斯的明之间无差异(比值比,0.95;95%置信区间,0.86 - 1.04;P = 0.281)。因此,在接受全身麻醉的患者中,与新斯的明相比,舒更葡糖钠和吡啶斯的明可能会降低PONV的发生率。